Considerations for Endpoints in Lung Transplant Clinical Trials: Perspective on the ISHLT Consensus Statement

By afschroeder • January 19, 2026

Greenland JR, Perch M, Halloran K, Levine DJ, Morrell ED, Reed A, Shaver CM, Singer JP, Sweet SC, Vos R, Aryal S, Avdimiretz N, Burrows F, Calabrese D, Calabrese F, Campos S, Combs M, de Perrot M, Dellgren G, Diamond JM, Egan T, Ging P, Glidden DV, Goddard M, Jyothula S, Keller M, Kulkarni H, Kwakkel-van Erp JM, Lama V, Marczin N, Martinu T, Neely ML, Palmer SM, Patterson CM, Pavlisko EN, Pham C, Sanchez M, Schultz HHL, Schwerk N, Shah U, Shashaty M, Singer L, Smith P, Snyder LD, Solomon M, Verleden S, Verplancke V, Zeevi A, Todd JL. Considerations for Endpoints in Lung Transplant Clinical Trials: Perspective on the ISHLT Consensus Statement. J Heart Lung Transplant. 2026 Feb;45(2):168-171. doi: 10.1016/j.healun.2025.09.016. PMID: 41548963.

Tags: Antibody-mediated rejection (AMR), Chronic lung allograft dysfunction (CLAD), Clinical trial endpoints, Lung transplantation, Patient-reported outcomes (PROs), Primary Graft Dysfunction, Publications, Pulmonary, Critical Care & Sleep Medicine

Communicating Precision Medicine Research: Multidisciplinary Teams and Diverse Communities

Beans JA, Trinidad SB, Blacksher E, Hiratsuka VY, Spicer P, Woodahl EL, Boyer BB, Lewis CM Jr, Gaffney PM, Garrison NA, Burke W. Communicating Precision[...]

A Spanish-language educational intervention to enhance diabetes outcomes among existing continuous glucose monitor users in a federally qualified health care center

Tavares M, Khoshbin K, Solorzano W, Scarlett L, Santana C, Lopez R, Villanueva GP, Escobar B, Mangual KS, Pavlish C, Bush NJ, Moin T, Everett[...]

Autosomal allelic inactivation at loci with variable replication timing and dosage sensitivity

Heskett MB, Vouzas AE, Johnstone B, Freese KP, Yates PA, Copenhaver PF, Spellman PT, Gilbert DM, Thayer MJ. Autosomal allelic inactivation at loci with variable[...]